Pacific Bio (PACB) Tops Q4 EPS by 2c
Get Alerts PACB Hot Sheet
Join SI Premium – FREE
Pacific Bio (NASDAQ: PACB) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $25.7 million versus the consensus estimate of $23.14 million.
For earnings history and earnings-related data on Pacific Bio (PACB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novartis (NVS) Tops Q1 EPS by 13c, raises guidance
- SAP SE (SAP) Misses Q1 EPS by 25c; offers outlook
- Pinnacle Financial Partners (PNFP) Tops Q1 EPS by 3c; offers outlook
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!